JP7512278B2 - 肺腫瘍の検出におけるメチル化dna、rna、及びタンパク質の特性決定 - Google Patents

肺腫瘍の検出におけるメチル化dna、rna、及びタンパク質の特性決定 Download PDF

Info

Publication number
JP7512278B2
JP7512278B2 JP2021530259A JP2021530259A JP7512278B2 JP 7512278 B2 JP7512278 B2 JP 7512278B2 JP 2021530259 A JP2021530259 A JP 2021530259A JP 2021530259 A JP2021530259 A JP 2021530259A JP 7512278 B2 JP7512278 B2 JP 7512278B2
Authority
JP
Japan
Prior art keywords
methylation
marker
max
dna
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021530259A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513658A5 (cg-RX-API-DMAC7.html
JP2022513658A (ja
Inventor
アラーウィ,ハティム
ピー. リドガード,グラハム
ギアクモプロス,マリア
エー. アールクイスト,デビッド
アール. テイラー,ウィリアム
マホーニー,ダグラス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Clinic in Florida
Original Assignee
Mayo Clinic in Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Clinic in Florida filed Critical Mayo Clinic in Florida
Publication of JP2022513658A publication Critical patent/JP2022513658A/ja
Publication of JP2022513658A5 publication Critical patent/JP2022513658A5/ja
Priority to JP2024103130A priority Critical patent/JP2024123233A/ja
Application granted granted Critical
Publication of JP7512278B2 publication Critical patent/JP7512278B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/107—Nucleic acid detection characterized by the use of physical, structural and functional properties fluorescence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Rehabilitation Therapy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2021530259A 2018-11-27 2019-11-26 肺腫瘍の検出におけるメチル化dna、rna、及びタンパク質の特性決定 Active JP7512278B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024103130A JP2024123233A (ja) 2018-11-27 2024-06-26 肺腫瘍の検出におけるメチル化dna、rna、及びタンパク質の特性決定

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862771965P 2018-11-27 2018-11-27
US62/771,965 2018-11-27
PCT/US2019/063401 WO2020112869A1 (en) 2018-11-27 2019-11-26 Characterizing methylated dna, rna, and proteins in the detection of lung neoplasia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024103130A Division JP2024123233A (ja) 2018-11-27 2024-06-26 肺腫瘍の検出におけるメチル化dna、rna、及びタンパク質の特性決定

Publications (3)

Publication Number Publication Date
JP2022513658A JP2022513658A (ja) 2022-02-09
JP2022513658A5 JP2022513658A5 (cg-RX-API-DMAC7.html) 2022-12-06
JP7512278B2 true JP7512278B2 (ja) 2024-07-08

Family

ID=70853661

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021530259A Active JP7512278B2 (ja) 2018-11-27 2019-11-26 肺腫瘍の検出におけるメチル化dna、rna、及びタンパク質の特性決定
JP2024103130A Pending JP2024123233A (ja) 2018-11-27 2024-06-26 肺腫瘍の検出におけるメチル化dna、rna、及びタンパク質の特性決定

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024103130A Pending JP2024123233A (ja) 2018-11-27 2024-06-26 肺腫瘍の検出におけるメチル化dna、rna、及びタンパク質の特性決定

Country Status (10)

Country Link
US (1) US20220136058A1 (cg-RX-API-DMAC7.html)
EP (1) EP3886878A4 (cg-RX-API-DMAC7.html)
JP (2) JP7512278B2 (cg-RX-API-DMAC7.html)
KR (2) KR102945867B1 (cg-RX-API-DMAC7.html)
CN (1) CN113423410A (cg-RX-API-DMAC7.html)
AU (1) AU2019389008A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021009795A2 (cg-RX-API-DMAC7.html)
CA (1) CA3119329A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021005963A (cg-RX-API-DMAC7.html)
WO (1) WO2020112869A1 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673555B2 (en) 2008-02-15 2014-03-18 Mayo Foundation For Medical Education And Research Detecting neoplasm
US8916344B2 (en) 2010-11-15 2014-12-23 Exact Sciences Corporation Methylation assay
US8361720B2 (en) 2010-11-15 2013-01-29 Exact Sciences Corporation Real time cleavage assay
EP2971179B1 (en) 2013-03-14 2019-01-09 Mayo Foundation for Medical Education and Research Detecting neoplasm
US10301680B2 (en) 2014-03-31 2019-05-28 Mayo Foundation For Medical Education And Research Detecting colorectal neoplasm
US10184154B2 (en) 2014-09-26 2019-01-22 Mayo Foundation For Medical Education And Research Detecting cholangiocarcinoma
WO2016160454A1 (en) 2015-03-27 2016-10-06 Exact Sciences Corporation Detecting esophageal disorders
JP6871926B2 (ja) 2015-08-31 2021-05-19 マヨ ファウンデーション フォア メディカル エデュケーション アンド リサーチMayo Foundation for Medical Education and Research 胃の新生物を検出すること
CA3002196C (en) 2015-10-30 2024-05-14 Exact Sciences Development Company, Llc Multiplex amplification detection assay and isolation and detection of dna from plasma
AU2017260630B2 (en) 2016-05-05 2023-07-13 Exact Sciences Corporation Detection of lung neoplasia by analysis of methylated DNA
AU2018211956B2 (en) 2017-01-27 2024-06-20 Exact Sciences Corporation Detection of colon neoplasia by analysis of methylated DNA
AU2018374176B2 (en) 2017-11-30 2024-12-12 Exact Sciences Corporation Detecting breast cancer
US10648025B2 (en) 2017-12-13 2020-05-12 Exact Sciences Development Company, Llc Multiplex amplification detection assay II
CA3127329A1 (en) 2019-01-24 2020-07-30 Mayo Foundation For Medical Education And Research Detecting endometrial cancer
WO2021041726A1 (en) * 2019-08-27 2021-03-04 Exact Sciences Development Company, Llc Characterizing methylated dna, rna, and proteins in subjects suspected of having lung neoplasia
EP4031683A4 (en) 2019-09-16 2024-01-17 Exact Sciences Corporation Structure and temperature-dependent flap endonuclease substrates
JP7799607B2 (ja) 2019-10-31 2026-01-15 マヨ ファウンデーション フォア メディカル エデュケーション アンド リサーチ 卵巣癌の検出
US11898199B2 (en) 2019-11-11 2024-02-13 Universal Diagnostics, S.A. Detection of colorectal cancer and/or advanced adenomas
WO2021228418A1 (en) 2020-05-15 2021-11-18 Universal Diagnostics, S.L. Methods and systems for identifying methylation biomarkers
EP4150121A1 (en) 2020-06-30 2023-03-22 Universal Diagnostics, S.A. Systems and methods for detection of multiple cancer types
EP3945135A1 (en) * 2020-07-27 2022-02-02 Les Laboratoires Servier Biomarkers for diagnosing and monitoring lung cancer
EP4284951A4 (en) * 2021-01-29 2025-05-28 Mayo Foundation for Medical Education and Research DETECTION OF THE PRESENCE OR ABSENCE OF MULTIPLE CANCERS
CN122081501A (zh) * 2021-06-22 2026-05-26 江苏鹍远生物科技股份有限公司 检测肺癌的dna甲基化标志物及应用
US20250361563A1 (en) * 2022-06-10 2025-11-27 Suzhou Huhu Health Technology Co., Ltd Methods, compositions, and kits for detecting malignant lung nodules and lung cancer
CN117385027A (zh) * 2022-07-04 2024-01-12 江苏鹍远生物科技股份有限公司 肺癌特异性甲基化标志物及其诊断肺癌的应用
CN115725734B (zh) * 2022-08-10 2023-10-13 人和未来生物科技(长沙)有限公司 Znf781基因在制备宫颈癌诊断试剂中的应用
KR102701683B1 (ko) * 2022-10-31 2024-09-02 주식회사 지씨지놈 폐암 진단용 dna 메틸화 마커 및 이의 용도
US12606872B2 (en) 2022-11-16 2026-04-21 Universal Diagnostics, S.A. Methods for stratification and early detection of advanced adenoma and/or colorectal cancer using DNA methylation markers
WO2025130881A1 (zh) * 2023-12-19 2025-06-26 上海交通大学医学院 一种诊断或治疗免疫系统疾病的生物标志物或靶点
CN118834956B (zh) * 2024-09-24 2024-12-06 上海信诺佰世医学检验有限公司 引物和探针组合物、试剂盒及在检测emx1、chfr基因甲基化中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010064702A1 (ja) 2008-12-05 2010-06-10 国立大学法人 東京大学 癌の予後を予測するためのバイオマーカー

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070264659A1 (en) * 2006-05-11 2007-11-15 Sungwhan An Lung cancer biomarker discovery
US20110318738A1 (en) * 2008-12-23 2011-12-29 University Of Utah Research Foundation Identification and regulation of a novel dna demethylase system
JP2014531213A (ja) * 2011-09-30 2014-11-27 ジェネンテック, インコーポレイテッド 上皮又は間葉の表現型の診断用メチル化マーカー、及び腫瘍又は腫瘍細胞におけるegfrキナーゼ阻害薬に対する応答
WO2013070950A1 (en) * 2011-11-08 2013-05-16 University Of Southern California Identification of a dna methylation marker for blood-based detection of ovarian cancer
US9546403B1 (en) * 2011-12-14 2017-01-17 University Of Utah Research Foundation Substrate for methylated DNA testing
WO2016094813A1 (en) * 2014-12-12 2016-06-16 Exact Sciences Corporation Compositions and methods for performing methylation detection assays
JP6877704B2 (ja) * 2015-11-16 2021-05-26 公立大学法人名古屋市立大学 膵臓癌の検出のための方法及びキット
AU2017260630B2 (en) * 2016-05-05 2023-07-13 Exact Sciences Corporation Detection of lung neoplasia by analysis of methylated DNA
RU2018145532A (ru) * 2016-06-21 2020-07-23 Зе Уистар Инститьют Оф Анатоми Энд Байолоджи Композиции и способы диагностирования раковых заболеваний легких с помощью профилей экспрессии генов
US11345949B2 (en) * 2016-07-19 2022-05-31 Exact Sciences Corporation Methylated control DNA

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010064702A1 (ja) 2008-12-05 2010-06-10 国立大学法人 東京大学 癌の予後を予測するためのバイオマーカー

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BMC Medical Genomics,2014年,7:18,p.1-8,http://www.biomedcentral.com/1755-8794/7/18
Journal of Pathology,2015年,Vol.235,p.397-407,DOI: 10.1002/path.4469
PLoS ONE,2011年,Vol.6, Issue 12,e28141
日本分子腫瘍マーカー研究会誌,2012年,Vol.27,p.65-66,doi.org/10.11241.jsmtmr.27.65
日本分子腫瘍マーカー研究会誌,2014年,Vol.29,p.22-23,doi.org/10.11241.jsmtmr.29.22

Also Published As

Publication number Publication date
CN113423410A (zh) 2021-09-21
KR20260066094A (ko) 2026-05-12
EP3886878A1 (en) 2021-10-06
US20220136058A1 (en) 2022-05-05
AU2019389008A1 (en) 2021-06-03
CA3119329A1 (en) 2020-06-04
BR112021009795A2 (pt) 2021-08-17
EP3886878A4 (en) 2022-11-02
JP2022513658A (ja) 2022-02-09
JP2024123233A (ja) 2024-09-10
KR102945867B1 (ko) 2026-03-31
WO2020112869A1 (en) 2020-06-04
MX2021005963A (es) 2021-08-24
KR20210099044A (ko) 2021-08-11

Similar Documents

Publication Publication Date Title
AU2023248106B2 (en) Detection of lung neoplasia by analysis of methylated DNA
JP7670662B2 (ja) メチル化dnaの分析による腫瘍の検出
JP2024123233A (ja) 肺腫瘍の検出におけるメチル化dna、rna、及びタンパク質の特性決定
JP7293109B2 (ja) 肝細胞癌の検出
JP7356349B2 (ja) 前立腺癌検出
US20220403471A1 (en) Characterizing methylated dna, rna, and proteins in subjects suspected of having lung neoplasia
HK40093169A (en) Detection of lung neoplasia by analysis of methylated dna

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230926

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240326

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240528

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240626